Amarin (AMRN) Volatility Nearly Double into PDUFA for AMR101
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Up)Join SI Premium – FREE
Amarin Corp. (Nasdaq: AMRN) volatility is slightly elevated on the session, but at 9 percent is nearly double the trailing annual average, heading into the pharma's PDUFA date tomorrow (July 26th) for AMR101.
Today, Amarin received notice of intention to grant letter for European Patent Application Number EP2395991, titled "Use of Eicosapentaenoic Acid Ethyl Ester for Treating Hypertriglyceridemia."
Amarin noted that this patent application "is intended to protect the exclusivity of Amarin's drug candidate, AMR101, for use in an indication that Amarin may seek through the European Medicines Agency (EMA)."
Shares of Amarin hit a new 52-week high last Thursday, and have held above at the upper-quarter of $14 or above since.
Today, Amarin received notice of intention to grant letter for European Patent Application Number EP2395991, titled "Use of Eicosapentaenoic Acid Ethyl Ester for Treating Hypertriglyceridemia."
Amarin noted that this patent application "is intended to protect the exclusivity of Amarin's drug candidate, AMR101, for use in an indication that Amarin may seek through the European Medicines Agency (EMA)."
Shares of Amarin hit a new 52-week high last Thursday, and have held above at the upper-quarter of $14 or above since.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
- Otis Worldwide (OTIS) May option implied volatility into quarter results
- Boeing (BA) April weekly option implied volatility into quarter results
Create E-mail Alert Related Categories
FDA, Insiders' Blog, OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
